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Abstract
Background:  The identification of novel drug targets by assessing gene functions is most
conveniently achieved by high-throughput loss-of-function RNA interference screening. There is a
growing need to employ primary cells in such screenings, since they reflect the physiological
situation more closely than transformed cell lines do. Highly miniaturized and parallelized
approaches as exemplified by reverse transfection or transduction arrays meet these requirements,
hence we verified the applicability of an adenoviral microarray for the elucidation of gene functions
in primary cells.
Results: Here, we present microarrays of infectious adenoviruses encoding short hairpin RNA
(shRNA) as a new tool for gene function analysis. As an example to demonstrate its application, we
chose shRNAs directed against seven selected human protein kinases, and we have performed
quantitative analysis of phenotypical responses in primary human umbilical vein cells (HUVEC).
These microarrays enabled us to infect the target cells in a parallelized and miniaturized procedure
without significant cross-contamination: Viruses were reversibly immobilized in spots in such a way
that the seeded cells were confined to the area of the viral spots, thus simplifying the subsequent
addressing of genetically modified cells for analysis. Computer-assisted image analysis of
fluorescence images was applied to analyze the cellular response after shRNA expression. Both the
expression level of knock-down target proteins as well as the functional output as measured by
caspase 3 activity and DNA fractionation (TUNEL) were quantified.
Conclusion: We have developed an adenoviral microarray technique suitable for miniaturized and
parallelized analysis of gene function. The practicability of this technique was demonstrated by the
analysis of several kinases involved in the activation of programmed cell death, both in tumor cells
and in primary cells.
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Background
In the years following the completion of the human
genome sequencing projects, a variety of genome-wide
screening procedures for functional analysis were devel-
oped. For instance, plasmid vectors were applied to trans-
fer cDNA for over-expression, or, alternatively, shRNA
knock-down cassettes for gene silencing [1]. To this end,
different plasmid vectors complexed with transfection rea-
gents were immobilized in microspots delivered to planar
glass slides, which were subsequently covered with a mon-
olayer of cells. The cells took up the genetic information
(reverse transfection) and phenotypic alterations were
functionally assayed [1]. However, many primary cells are
not amenable to classical transfection protocols. In these
cases viral vectors are the only means to genetically
manipulate the target cells. This instigated us to test the
suitability of viral vectors for arraying, for which purpose
we have chosen adenovirus as a model. In the meantime,
similar arraying experiments were carried out using lenti-
virus [2] and retrovirus [3].
We have generated a microarray of infectious adenovirus
to convey genetic information into the target cells (reverse
infection). By choosing an adequate blocking procedure,
we managed to strictly confine the cells to the viral spots,
preventing adherence to areas without genetic informa-
tion. By co-expressing fluorescent markers, we could dif-
ferentiate infected cells from non-infected cells, thus
facilitating phenotypic analysis.
We have employed the adenoviral array technology to
analyze the contribution of seven protein kinases to cell
signalling in HUVEC after viral transfer of validated
shRNA expression cassettes. This group of enzymes was
selected to exemplify the application of miniaturized ade-
noviral arrays.
Results
Reverse transduction by arrayed adenovirus
The use of adenoviruses has been demonstrated for mini-
aturized high-throughput virus production as well as
transduction in microwell plates [4]. A novel printing
technique was developed to print arrayed adenovirus on
glass slides for the subsequent infection of cells seeded on
top (Fig. 1A). The viruses were immobilized in defined
spots (diameter approx. 80 μm), and the surface outside
the spots was blocked in a way that only the area of the
viral spots was permissive to eukaryotic cell adhesion.
Hence, the pattern of immobilized adenovirus was
reflected by the formation of a corresponding cell array
(Fig. 1A). This approach facilitates phenotypic analysis, as
the cells to be investigated are spatially confined (Fig. 1B).
Adenoviral vectors applied in Figure 1 were constructed to
express enhanced green fluorescent protein (EGFP) or red
fluorescent protein (RFP) as markers for the identification
of infected cells. In addition, they contain Gateway™
recombination sites for high-throughput introduction of
shRNA expression cassettes after in vitro recombination.
Successful infection was assayed by EGFP or RFP fluores-
cence analysis. The appearance of EGFP/RFP-positive cells
indicated that the immobilized viruses maintained their
infectivity, and no significant intermixture occurred
between neighboring viral spots (Fig. 1C). This finding
was further supported by quantification of EGFP fluores-
cence in spots with RFP-expressing adenoviruses, and vice
versa  (Fig. 1D). Likewise, release of adenoviruses from
spots was not observed when the washing buffer was
tested for infectious particles (data not shown). Hence,
the viruses were sufficiently immobilized to prevent cross-
contamination between the spots, yet immobilized cells
were still able to take up viral particles for infection.
The infectivity rate of reverse transduction was measured
by comparing the number of EGFP-positive cells with the
number of DAPI-stained nuclei. In the case of the osteosa-
rcoma cell line U-2 OS, infection of approximately 70% of
all cells was achieved (Fig. 1E). We found the chips with
immobilized adenoviruses to remain infective for more
than two weeks when stored at 4°C, without significant
loss in overall infectivity (see Additional file 1).
In conclusion, arrayed adenoviruses are able to transduce
cells efficiently, and the adenoviral arrays generated can
be readily stored for prolonged time-periods without
loosing infectivity, meaning this technology to be applica-
ble for the large-scale applications.
shRNA-mediated knock-down on a chip
An imaging procedure with the help of ImageJ http://
rsbweb.nih.gov/ij/ was used to calculate knock-down of
target genes by quantitative analysis of immunstainings.
The principles of the analysis are explained in Figure 2A.
U-2 OS cells were seeded onto the adenoviral array, and
infected cells were identified by RFP fluorescence (Fig. 2A,
left image). Lamin A/C expression was visualized by indi-
rect Cy2 immunofluorescence microscopy (Fig 2A, right
image). For quantitative analysis, the fluorescence inten-
sity of infected cells was determined by computer-assisted
image analysis. In order to electronically evaluate the
cells, the ROI (regions of interest) were defined using RFP
fluorescence, indicative of adenoviral infection: To this
end, the images were subjected to image segmentation.
During the segmentation process, images were binarized
by setting a defined threshold value for pixel intensity,
and subsequently assigning the value of "black" to all pix-
els with an intensity above the threshold, and a value of
"white" to all pixels with an intensity below the threshold.
Hence, "black" pixels correspond to areas where infected
cells are located, allowing to discriminate image regions
containing infected cells from regions without infectedBMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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Immobilization of viral spots in a microarray format Figure 1
Immobilization of viral spots in a microarray format. A. Adenovirus encoding shRNAs directed against different target 
genes (1, 2, 3, ..., n) are immobilized on a glass slide. B. Coomassie staining of HeLa cells seeded on the adenoviral microarray. 
Due to the thickness of the carrier (glass-slide), shadows of the printed spots were cast on the stage plate of the microscope. 
This "shadowing" is not observed by using conventional fluorescence microscope, used for image analysis. Scale bar, 100 μm. 
C. Neighbouring spots of U-2 OS cells on the microarray. The cells were alternately infected with two types of adenoviruses, 
encoding either enhanced green fluorescent protein (EGFP) or red fluorescent protein (RFP), respectively. Scale bar, 100 μm. 
D. Quantitative analysis of viral spots, eight spots for each fluorescence marker, from Figure 1C for the detection of intermix-
ture between neighbouring viral spots. E. Infection efficiency of U-2 OS cells: Percentage of the number of cells expressing 
EGFP compared to total number of cells as determined via DAPI stain (4 spots, n > 150).BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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Analysis of lamin knock-down in U-2 OS cells seeded on an adenoviral microarray Figure 2
Analysis of lamin knock-down in U-2 OS cells seeded on an adenoviral microarray. A. Fluorescent micrographs of 
cells expressing RFP and shCTR stained with antibody directed against lamin A/C. Red fluorescence (left) indicates infected 
cells, green fluorescence (right) indicates lamin A/C expression. The diagram illustrates the evaluation procedure. Scale bar, 10 
μm. B. Bar diagram, showing the averages of fluorescence intensity of the lamin A/C immunostaining of U-2 OS cells express-
ing either an irrelevant shRNA (shCTR), or shRNA directed against lamin A/C (shLamin) [5] for the experiments performed 
on the chip (black bars) or in the 96-well plate (gray bars). Infection efficiency achieved on the microarray as well as in the well 
suffices to elicit a significant knock-down (4 spots, n > 150, p < 0.005; by ANOVA analysis). C. Validation of shRNA targeting 
Lamin A/C by Western immunoblot analysis. U-2 OS cells were transfected either with pENTR +pcDNA3-eGFPneo (lane 1) 
or with pENTR-shLaminA/C +pcDNA3-eGFPneo (lane 2) and the lysates were immunoassayed 48 hours later.BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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cells, and the former regions gave rise to the "regions of
interest" analysed further. Those ROIs (Fig 2A, center
image) were superimposed on the corresponding Cy2
images, and the intensity of lamin A/C immunostaining
was determined for each ROI (Fig 2A, right image).
Adenoviral vectors were arrayed on a chip encoding
shRNA directed against lamin A/C (shLamin) [5] in addi-
tion to an RFP expression cassette. As a control, adenovi-
rus encoding an irrelevant shRNA (shCTR) was
introduced. This shCTR contains an shRNA sequence with
no homology to human genes, as confirmed by BLAST
search. Fluorescence intensities of the cells infected by the
control adenovirus were compared to the one of the cells
infected by the shLamin expressing virus as depicted in a
bar chart (Fig. 2B). Compared to the control, lamin A/C
expression was decreased in the case of the cells trans-
duced with an adenoviral vector expressing lamin-specific
shRNA, indicative of an overall reduction in lamin A/C
expression.
Hence, our results show that shRNA-mediated knock-
down is feasible in cells exposed to adenoviral arrays.
Validating the adenoviral arrays in functional assays – 
comparison to conventional infection
A panel of seven adenoviral vectors expressing shRNAs
directed against human protein kinases was applied to
analyze the phenotypic response of tumor cells after gene
silencing. The protein kinases selected are known to be
involved in the regulation of apoptosis (BTK (Bruton's
tyrosine kinase) [6-8], p38alpha (also known as
MAPK14) [9-11]), in cell cycle progression (cyclin-
dependent kinase 2, CDK2 [12-14], PKN1 [15]) or in
mitotic regulation (NEK2 (also known as NIMA) [16-18]
and PBK (PDZ binding kinase) [19,20]). Furthermore,
one protein kinase was included for which no effect on
apoptosis had been described (TrkA [21]). The shRNA
sequences were validated and reduced protein kinase
mRNA levels to ≤ 40% compared to the control shRNA
(shCTR) in a reporter psiCheck™-2 assay (Fig. 3A). Luci-
ferase activity was normalized to cells co-transfected with
psiCHECK and shCTR. Three independent experiments
have been carried out and the standard deviations are
given. These kinase-specific shRNA adenoviral vectors
were printed in arrays, and U-2 OS cells were immobilized
as described above.
The induction of apoptosis was determined either by ter-
minal-deoxynucleotidyl-transferase-mediated dUTP-
biotin nick end labelling (TUNEL), or by immunodetec-
tion of cleaved caspase 3. A representative set of micro-
graphs is given in Figure 3B, in which infected cells were
identified using EGFP fluorescence (Fig. 3B, top images),
whereas red fluorescence indicated incorporation of rhod-
amine-labelled dUTP or the presence of activated caspase-
3 (TUNEL or cleaved caspase-3 staining, Fig. 3B, centre
images). A merger of both micrographs is likewise given
(Fig. 3B, lower images), in which yellow indicates a strong
TUNEL- or caspase 3-signal. As a result, a strong induction
of cell death upon knock-down of p38alpha in U-2 OS
cells was detected.
Fluorescence intensities of both activated (cleaved) cas-
pase 3 and TUNEL in comparison to cells infected with
the control adenovirus (shCTR) were quantified as out-
lined above. The induction factor observed using activated
caspase 3 or TUNEL staining as a determinant was up to
4-fold (Fig 3C). The knock-down of the four kinases
p38alpha, PKN1, NEK2 and PBK evoked apoptosis as
determined via caspase 3 activation compared to the con-
trol infection (p < 0.005). The same four kinases were
identified as targets using the TUNEL assay (p < 0.005).
Hence, using two independent assays for apoptosis detec-
tion, we could demonstrate the feasibility of functional
assays on the adenoviral chips.
In Figure 3D, the functional assay performed on the ade-
noviral array was compared with the conventional assay
using transfection of U-2 OS cells in a 96 well format: The
induction of apoptosis on the array was determined by the
detection of activated caspase 3 as described above,
whereas the induction of apoptosis in the 96-well plate
was determined by measuring the enzymatic activity of
caspase 3 using a proluminescent caspase 3 substrate
(Caspase-Glo® 3/7 Assay, Promega), which is adapted to
high-throughput cellular assay systems. In this kind of
assay, the generated luminescence is proportional to the
amount of caspase activity present. For comparison,
shRNA sequences against two anti-apoptotic kinases,
p38alpha and PKN1, as well as an shRNA sequence
against CDK2, the knock-down of which did not induce
apoptosis, were chosen, and the induction of caspase 3
activity was depicted. Induction of apoptosis after shRNA-
mediated knock-down of p38alpha and PKN1 exceeded
the signals of the well-based assay which indicated that
the adenoviral chip is a suitable alternative to the well-
based assays. No induction of apoptosis was observed
with either assay after expression of the vector specific for
the knock-down of CDK2.
The signal-to-noise ratios (S/N) in Fig. 3D were calculated
as a ratio of the difference between mean signal and mean
background values to the background standard deviation
[22] in order to compare the sensitivity of the on-chip
assay with the in-well assays. For the experiment per-
formed on the chip, they amount to: 5.7 (p38alpha); 2.4
(CDK2); 9.2 (PKN1). For the in-well trials, they amount
to: 1.2 (p38alpha); 0.8 (CDK2); 2.1 (PKN1). Similar
experiments using TUNEL assay were not performed.BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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Functional assays using primary HUVEC
The advantage of adenoviral infection lies in the fact that
adenoviruses allow the genetic manipulation of cells not
amenable to classical transfection protocols, such as many
primary cells. To make use of this advantage, we investi-
gated both the efficiency of the knock-down and the
employability of a functional assay using primary human
umbilical vein endothelial cells (HUVEC). The knock-
down efficiency was analyzed by seeding HUVEC onto a
microspot array of immobilized adenovirus encoding RFP
as well as shRNA directed against lamin A/C (shLamin).
As a control, adenoviruses encoding RFP as well as a con-
trol shRNA (shCTR) were likewise printed. A comparative
quantitative analysis was conducted as described above,
the result of which is presented in a percentile diagram
(Fig. 4A) as well as in a bar chart (Fig. 4B). Compared to
the control situation, a significant reduction of fluores-
cence intensities was observed in cells infected with aden-
ovirus expressing shRNA specific for lamin A/C. Hence,
the overall reduction in lamin A/C expression indicated
that adenoviral arrays are also applicable to human pri-
mary cells. Adenoviral arrays yielded levels of lamin A/C
knock-down of 30–40% in HUVEC cells, which were
quantitatively similar to the levels observed in U-2 OS
cells.
Next, we asked whether an array of kinase-specific shRNA
expressing adenoviruses would result in detectable induc-
tion of apoptosis in HUVEC. As shown above for U-2 OS
cells, HUVEC were exposed to arrayed adenoviral shRNA
vectors and activated caspase 3 was detected by immun-
ofluorescence analysis. Figure 4C demonstrates induction
of apoptosis in HUVEC after infection with shRNA
directed against PBK. Here, similar to Figure 3B, infected
cells were identified using EGFP fluorescence (Fig. 4C, top
images), whereas red fluorescence indicated incorpora-
tion of Cy3-labelled antibodies against cleaved caspase 3
(Fig. 4C, centre images). A merger of both micrographs is
likewise given (Fig. 4C, lower images), in which yellow
indicates a strong activation of programmed cell death. As
can be inferred from Figure 4D, the maximal induction of
apoptosis was approx. 3-fold in comparison to the control
vector (shCTR). The induction factors observed were sig-
nificantly different when compared to the control situa-
tion (p < 0.005) and within a similar range as those found
after transduction of U-2 OS cells.
Whereas the knock-down of NEK2 and PBK induced
apoptosis in both HUVEC and U-2 OS cells, the cells dif-
fered in their response to the knock-down viruses against
BTK, CDK2, p38alpha1, and PKN1: The knock-down of
the former resulted in apoptosis in HUVEC, and the
knock-down of the latter evoked apoptosis in U-2 OS.
In conclusion, we show that adenoviral arrays are suitable
to perform functional assays even in primary cells. Hence,
the adenoviral microarray allows a comparative analysis
of kinase functions in different cell types under miniatur-
ized and parallelized conditions.
Discussion
Multiple RNAi platforms are now available for performing
large-scale loss of function screens on mammalian cells.
Viral-based screens have been introduced for their prom-
ise in expanding RNAi screens to models incompatible
with conventional siRNA-based approaches.
We present here a microarray suitable for miniaturized
and parallelized genetic manipulation and screening of
primary human cells. As a vector for gene transfer we have
employed adenoviruses. The viral vector system applied
needs to include stable viral particles to enable long-term
storage and transport. Additionally, high-throughput
applications for genome-wide screenings require the pos-
sibility to produce virus in a small scale, miniaturized for-
mat, properties which are adequately met by adenoviral
vectors.
Detection of apoptosis induction in U-2 OS cells seeded on an adenoviral microarray Figure 3 (see previous page)
Detection of apoptosis induction in U-2 OS cells seeded on an adenoviral microarray. A. Relative expression levels 
of the target genes indicated after co-transfection of the psiCHECK marker plasmid and shRNA-encoding plasmids directed 
against the target genes indicated. B. TUNEL assay (left part of the image) or immunofluorescence of anti-cleaved caspase 3 
(right part of the figure) of cells expressing EGFP and either control shRNA (left) or shRNA directed against p38alpha (right). 
Top, green fluorescence indicating infected cells; centre, red fluorescence for detection of TUNEL-positive cells or cells posi-
tive for cleaved caspase 3; bottom, merged images. Scale bar, 20 μm (for TUNEL) and 10 μm (for cleaved caspase 3 immunos-
taining). C. Functional assays performed on the microarray, using shRNA sequences directed against the target genes indicated. 
Caspase 3 (black bars) or TUNEL signal (hatched bars) were quantified in U-2 OS cells (ImageJ software). The statistical signif-
icance is marked by asterisks (4 spots, n > 150, p < 0.005, three independent experiments; by ANOVA analysis). D. Compari-
son of caspase 3 activation using either immunodetection on the microarray (black bars), or detection of enzymatic caspase 3 
activity in cell lysates (Caspase-3-Glo, in a 96-well format (hatched bars). Statistical significance is marked by asterisks (4 spots, 
n > 150, p < 0.005, three independent experiments; by ANOVA analysis). On the right, the calculations of signal-to-noise ratios 
are shown.BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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Application of the adenoviral microarray to primary human cells (HUVEC) Figure 4
Application of the adenoviral microarray to primary human cells (HUVEC). A. Percentile diagram showing the dis-
tribution of immunofluorescence intensity of HUVEC, indicative of lamin A/C: Cells were infected with adenovirus encoding 
either shCTR (open circles) or shLamin (closed circles) (p < 0.005; n > 150; by ANOVA analysis). B. Bar chart corresponding 
to the Lamin A/C expression levels shown in Fig. 4A: shCTR (white bars), shLamin (black bars) (p < 0.005; n > 150; by ANOVA 
analysis). C. Representative immunofluorescent images of HUVEC cells analysed in Figure 4D: Cells were infected with adeno-
virus encoding either shCTR (left), or shPBK (right). Green fluorescence (top) indicates infected cells, red fluorescence (mid-
dle) is indicative of activated caspase 3, merged images (bottom). Scale bar, 20 μm. D. Detection of apoptosis by 
immunostaining of α-cleaved caspase 3, using adenoviruses encoding specific shRNAs as indicated. The asterisks mark signifi-
cant induction of apoptosis (4 spots, n > 150, p < 0.005; three independent experiments; by ANOVA analysis). TUNEL assay 
was not performed using HUVEC cells.BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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In addition to the adenoviral microarray presented here, a
similar system was also reported for lentiviral [2] and ret-
roviral [3] shRNA expression vectors. Adenoviral and len-
tiviral screening platforms may be advantageous when
assays are to be performed in primary, nondividing/differ-
entiated cells or in established cell lines refractory to trans-
fection. The technology of viral immobilization is
comparable in all the cases: they rely on the principle of
"reverse transduction/infection". The viral stocks are
printed manually or automatically on glass slides coated
with γ-amino propyl silane in the case of lentiviral micro-
arrays, with a nanostructured titanium dioxide film in the
case of retroviral microarrays, or with nitrocellulose for
adenoviral microarrays. These printed chips can be stored
or used directly. The production of high-titer viral parti-
cles in miniaturized 96-well format had earlier been dem-
onstrated for lentiviruses [23,24], retroviruses [25] and for
adenoviruses [26].
The decision as to which technology of viral delivery to
employ will be situational as each of these three
approaches comes along with distinct advantages and
drawbacks. The advantage of the adenoviral microarray
system presented in this study is an application of an
appropriate blocking solution after printing the adenovi-
rus. This implementation serves to confine cell adherence
to the distinct spots containing the genetic information.
Such confinement resulted in an array of cells, signifi-
cantly simplifying identification in subsequent analysis.
Additionally, it results in a reduced number of cells
required for screening, which is especially relevant for the
screening of primary cells, as the amount of cells available
is frequently restricted. Whether the blocking step is appli-
cable to the lentiviral microarray or any other viral system
remains to be shown. As the viral vector system applied is
characterised by highly stable viral particles, storage and
transport of ready-to-use arrays is also feasible.
Genetic manipulations carried out in a microwell format
allow for the well-by-well analysis using biochemical
assays, the sensitivity of which needed to be achieved in a
microarray configuration by fluorescence imaging. We
have hence compared a sensitive well-based assay measur-
ing the induction of apoptosis via enzymatic activity of
caspase 3 in the lysate with immunodetection of activated
caspase 3 on the microarray. As judged by the signal-to-
noise ratios, the microarray-based assay provided signals
at least in the range of the in-well assay. For optimal sen-
sitivity, it should be noted that any assay carried out on a
microarray requires discrimination between cells which
have taken up shRNA constructs and untransduced cells.
Here we introduced adenoviral vectors which enable the
required discriminatory power, provided by a suitable
marker incorporated in the vector backbone.
In order to test the feasibility of the adenovirus array tech-
nology for unravelling signalling pathways in a model pri-
mary cell, we studied the influence of shRNA-mediated
knock-down of a set of seven protein kinases on the apop-
totic process. The applicability of the device for functional
assays on primary cells was exemplified using HUVEC.
The comparison of signals obtained infecting HUVEC or
U-2 OS cells revealed cell-type-specific responses to the
knock-down constructs directed against individual
kinases. The technology of the adenoviral siRNA microar-
ray allowed to quantitatively measure phenotypical differ-
ences between these two distinct cell lines and therefore
was qualified as a convenient and suitable tool for the
cell-based analysis. Nevertheless, for more fundamental
conclusions of the biological impact of these kinases, a
more detailed investigation is needed, e.g. by testing sev-
eral independent shRNA sequences directed against the
targets identified to rule out off-target effects.
The kinases analyzed have been chosen from two catego-
ries: On one hand, we have selected rather general inter-
players, such as PBK and NEK2, which have been shown
to be important for cell cycle progression, DNA damage,
and mitotic regulation [16,17,19,20]. On the other hand,
we have selected more specific interplayers: p38alpha,
BTK, PKN1 and CDK2 [6,8,9,12,13,15,27-29]. The knock-
down constructs against PBK and NEK2 drove both
HUVEC and U-2 OS cells into apoptosis, consistent with
their overall importance for cell cycle progression.
A more specific response was observed for p38alpha and
PKN1 in U-2 OS cells. These experiments suggest that
osteosarcoma cells exhibit a higher sensitivity towards
inhibition of kinases involved in the MAPK pathway than
HUVEC. On the contrary, the knock-down of the kinases
BTK and CDK2 elicited apoptosis in HUVEC but not in U-
2 OS cells. As it was reported by Cai et al., solely depleting
CDK2 was not sufficient to induce apoptosis in the oste-
osarcoma cell line U-2 OS [12].
The depletion of TrkA (also known as Ntrk1; neurotrophic
tyrosine kinase, receptor, type 1) showed no effect on the
induction of apoptosis in either cell type. This kinase
depends on a particular surface membrane receptor for
signal transmission, which might be absent or inactive in
the cells examined [21].
Conclusion
In general, the results on apoptosis induction upon
knock-down of particular targets using the adenoviral
chip correlated with published data
[8,13,15,16,18,19,21,27,28,30]. Additionally, the func-
tional assays performed using this practical microarray
technique allowed the preliminary identification of sev-
eral genes involved in the activation of apoptosis, both inBMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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tumor and in primary cells. The easy handling of the ade-
noviral microarrays, their suitability for immunochemical
studies and for other diverse applications, as well as the
possibility to acquire reliable results within a short period
of time – these are the advantages of the present system.
In addition, the suitability of adenoviral microarrays for
miniaturized and parallelized screening makes them an
attractive tool for a variety of scientific purposes.
Methods
Cell lines
HEK293 cells (CRL-1573, ATCC) and U-2 OS cells (HTB-
96, ATCC) were cultivated in DMEM (Gibco), comple-
mented with 200 mM Glutamin and 10% FCS (HyClone).
HUVEC (PromoCell) were cultivated in EBM-2 Bulletkit
medium (Cambrex).
Design and cloning of shRNA sequences
The shRNA sequences directed against human kinases
were based on siRNA sequences selected using public serv-
ers such as the Whitehead siRNA selection program http:/
/jura.wi.mit.edu/bioc/siRNAext/[31], the Sfold siRNA
design methodology program http://sfold.wadsworth.org
/index.pl[32], the GenScript siRNA Target Finder https://
www.genscript.com/ssl-bin/app/rnai, and the Dhar-
macon siDESIGN® Center http://www.dharmacon.com/
DesignCenter/DesignCenterPage.aspx. The shRNA 
sequences are available upon request.
For the generation of shRNA-expressing vectors, oligonu-
cleotide pairs were synthesized encompassing the siRNA
sequences (19 nt or 21 nt) and their reversely comple-
mentary sequences, connected by the spacer 5'-CGAA-3'.
Immediately downstream of the complementary
sequences, there is a stretch of five thymidine residues,
which serves as a stop signal for RNA polymerase III.
Hence, a transcript is generated that can form a hairpin
structure, in which the complementary sequences form
the stem and the spacer forms the loop [33,34].
The oligonucleotide pairs were annealed and ligated into
pENTR™/U6 according to the manufacturer's protocol
(BLOCK-iT™ U6 RNAi Entry Vector Kit, K4945-00, Invitro-
gen). In these vectors, the expression cassette – consisting
of the human U6 promoter and the shRNA sequences – is
flanked by the attachment sites attL1 and attL2, which
allow the transfer of the expression cassette into the aden-
oviral destination vectors by site-specific LR recombina-
tion. The vector pAdEasy1_EGFP_shRNA is used to raise
adenoviral stocks for printing as described below. A simi-
lar construct encoding RFP was likewise generated (Fig.
5).
Validation of shRNA sequences
For each kinase, the cDNA was cloned – sometimes only
partially – between the open reading frame of the human-
ized Renilla luciferase gene and a synthetic polyadenyla-
tion site of plasmid psiCHECK™-2 (C8021, Promega,
Genebank accession # AY535007). Depending on the
presence of suitable restriction sites upstream and down-
stream of the kinase open reading frames, modified ver-
sions of psiCHECK™-2 were generated with extended
multiple cloning sites. If no suitable restriction sites were
present, the cDNAs were amplified by PCR using primers
containing the desired restriction enzyme recognition
sites.
For the validation of the efficiency of the knock-down,
HEK293 cells were co-transfected with a psiCHECK™-2
derivative containing the target cDNA sequence and the
corresponding pENTR™/U6 plasmid encoding the shRNA.
The co-transfection was carried out in a 96-well format,
with 0.2 μg DNA/well using Lipofectamine™ 2000 Trans-
fection Reagent (11668-019, Invitrogen) according to the
manufacturer's protocol. Approx. 48 hours after transfec-
tion, the cells were lysed and the luciferase activity was
determined according to the manufacturer's instructions
(Dual-Glo™ Luciferase Assay System, E2920, Promega).
Only those shRNA sequences which reduced luciferase
activity by > 50% were transferred into a destination vec-
tor to generate the corresponding adenoviral shRNA
expression vector.
Western Blotting
The U-2 OS cells were transfected with the indicated con-
structs and 48 hours later the cells were lysed using Lae-
mmli Buffer, containing 2% SDS, 10% glycerol, 5% 2-
mercapto ethanol, 0,002% bromphenol blue and 0,075
M Tris HCl. Correlative to the transfection efficiency, an
appropriate amounts of the protein lysate were loaded on
10% SDS-PAGE gel. After transfer and blocking proce-
dures, the nitrocellulose membrane was incubated with
mouse anti-Lamin A/C antibody (1:5000 diluted, Nr.
05714, Upstate Biotechnology) following immunostain-
ing with HRP-conjugated rabbit anti-mouse secondary
antibody. The final blots were treated using ECL™ Plus
Western Blot Detection Reagent (RPN2132, GE Health-
care Life Sciences) for the detection of the signal.
Construction of adenoviral shRNA expression vectors
The adenoviral destination vectors used were
pAdEasy1_EGFP-DEST and pAdEasy1_RFP-DEST, which
contains the attR1-CmR-ccdB-attR2  cassette upstream of
the cassette for the expression of the marker genes
enhanced green fluorescent protein (EGFP) or red fluorescent
protein (RFP), respectively. These adenoviral vectors are
based on pAdEasy-1 (Stratagene), into which the above
mentioned cassettes were cloned by homologous recom-BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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bination using Escherichia coli BJ5183[35]. Furthermore,
the original ampicillin resistance gene was replaced by a
tetracycline resistance gene.
The attR1-CmR-ccdB-attR2 cassette was generated by BP
recombination between pDONR221 (Invitrogen) and a
suitable cassette containing attB1  and  attB2, using the
Gateway® BP Clonase™ II enzyme mix (11789020, Invitro-
gen) according to the manufacturer's instructions.
The EGFP expression cassette originated from pEGFP-N1
(Clontech; GenBank Accession # U55762) and contains
the immediate early promoter of CMV, the EGFP open
reading frame as well as the SV40 polyadenylation signal.
The RFP expression cassette originated from pDsRed-
Express-N1 (Clontech) and contains the immediate early
promoter of CMV, the RFP open reading frame as well as
the SV40 polyadenylation signal.
The shRNA expression cassettes in pENTR™/U6 were
transferred into the adenoviral destination vectors by site
specific recombination in vitro (Gateway® LR Clonase™ II
Enzyme Mix (11791020, Invitrogen).
The resulting vector pAdEasy1_EGFP_shRNA carries the
shRNA expression cassette as well as a marker gene under
the control of the CMV promoter. Hence, the cassette con-
taining the genes for Chloramphenicol resistance (CmR)
and the bacterial ccdB  gene is replaced by the shRNA
expression cassette. Concomitantly, the CmR-ccdB cassette
is transferred to the pENTR vector (Fig. 5).
Raising of adenoviral stocks and printing of adenoviral 
arrays
The adenoviral vector system used is based on the genome
of the human adenovirus serotype 5 (Ad5), from which
the early genes E1 and E3 have been deleted (AdEasy™
Adenoviral Vector System, Stratagene) [35,36]. Adenovi-
ruses were raised from HEK293 cells according to the
manufacturer's instructions in three rounds of amplifica-
tion. Briefly, HEK293 cells were transfected with corre-
sponding pAdEasy-CMV vector using Lipofecatmine 2000
(11668, Invitrogen) in a 6-well plate and the cells were
scraped off 13 days later. After a short centrifugation by
2000 rpm, the cells were resuspended in 1 ml of PBS and
subsequently submitted to 4 freeze-thaw cycles in liquid
nitrogen. For the first amplification 50% of the cells were
transferred to a 10 cm dish with HEK293 cells. The above
described procedure was repeated 10 days later for the sec-
ond amplification and 50% of the cells were used for the
infection of three 10 cm dishes. Finally, three days later
the procedure of virus concentration was repeated for the
third amplification and 50% of cells were used to infect 40
10 cm dishes. 5–7 days later the same procedure of virus
extraction was performed, the pellet was resuspended in
14 ml of PBS and an additional centrifugation by 10.000
rpm for 30 minutes was introduced after freeze-thaw
cycles. The supernatant was transferred in to new tubes
and frozen at -70°C.
The titres obtained after the third amplification were in
the range of 1 × 109 infectious units/ml. The adenoviral
stocks could be stored at -70°C over months without
loosing their infectious capacity by -70 C. The procedure
of virus generation is non-laborious and suitable for high-
throughput applications.
Adenoviral stocks, resuspended in PBS, were printed onto
glass slides covered with nitrocellulose, using a manual 8-
pin arrayer (MicroCASTer™, Schleicher & Schuell). Nitro-
cellulose covering was achieved by dipping the micro-
scopic slides in a 25 mg/ml solution of nitrocellulose
(N8267, Sigma-Aldrich) in methanol and subsequent
evaporation of the solvent under sterile conditions using
a laminar air flow bench.
The printed adenoviral chips were shown to be not
impaired in their infectious capacity till day 17 by storing
Transfer of validated shRNA expression cassettes into the  adenoviral genome Figure 5
Transfer of validated shRNA expression cassettes 
into the adenoviral genome. Site-specific recombination 
between attL1/2 and attR1/2 from the entry vector pENTR/
U6_shRNA into the adenoviral genome pAdEasy-1_EGFP-
DEST.BMC Genomics 2008, 9:441 http://www.biomedcentral.com/1471-2164/9/441
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at 4°C. Longer periods of storage are not recommended
since the viruses gradually loose their infectious capacity.
Infection on the chip and functional assays
After printing, the surface outside the viral spots was
blocked by the application of 1 ml of StabilGuard® (SG01,
SurModics, Eden Prairie, MN, USA) [37,38], passed
through a 0,2 μ filter, for 45 minutes and the slides were
subsequently washed with phosphate-buffered saline
(PBS).
4–5 × 105 trypsinized cells were distributed over the sur-
face of the chip, which was placed into a Petri dish. The
cells were left for 8–10 hours at 37°C in 5% CO2. Then,
fresh medium was added to the cells so that the chip was
completely covered with medium. Three (in the case of
cleaved caspase 3 measurement) or four (in the case of the
TUNEL assays) days later, the chips were washed twice
with PBS and fixed in 4% formaldehyde solution for 15
minutes. After a subsequent wash with PBS, the cells on
the chips were permeabilized using 0.25% Triton X-100 in
PBS for 15 min. To block unspecific binding of the anti-
bodies, the cells were blocked with 1% BSA (bovine serum
albumin) in PBS/Tween-20 for 30 minutes. Afterwards,
the chips were treated with either anti-lamin A/C mono-
clonal mouse antibody (SC-7292, Santa Cruz) or with
anti-cleaved-caspase-3 (Asp175) antibody (9661, Cell Sig-
nalling Technologies), diluted in 1% BSA-PBS solution,
for at least one hour at 37°C. After decanting the first anti-
body solution, the chips were washed three times with
PBS and incubated for 1 hour with secondary Cy2-cou-
pled goat anti-mouse antibody for lamin staining (115-
226-003, Dianova), or with Cy3-coupled goat anti-mouse
antibody for caspase-3 staining (115-116-003, Dianova).
Prior to mounting with DacoCytomation fluorescent
mounting medium (S3023, DakoCytomation), the chips
were counterstained for 1 minute with DAPI followed by
fluorescent microscopy analysis.
The TUNEL assay was performed using the In Situ Cell
Death Detection Kit, TMR Red (Roche Applied Science,
2156792) exactly following the manufacturer's instruc-
tions. Shortly, 4 days after infection, the chips were fixed
using the Fixation Solution provided with the kit for 1 h
at 25 C, washed with PBS and permeabilised with the Per-
meabilisation Solution from the kit for 2 minutes on ice.
After washing with PBS, the chips were overlaid with 100
μl of TUNEL reaction mixture, prepared according to the
provider, and kept for 1 hour at 37 C in the cell incubator.
After final washing with PBS, the chips were overlaid with
cover slips and analysed using a fluorescence microscope.
Microscopy and image evaluation procedure
The adenoviral spots were photographed using a micro-
scope (Zeiss Axiovert 200 M) supported by the AxioVision
LE Rel 4.5 software. The images were analyzed and evalu-
ated using the ImageJ (Version 1.38x) software. Spot
images from immunostaining with antibodies against
anti-cleaved caspase 3 or after TUNEL assay were con-
verted into 8-bit pictures and compared with shCTR
images using the Image Correlator plug-in.
For the evaluation of the lamin A/C knock-down, the flu-
orescent signal of the markers (EGFP or RFP) was used to
identify infected cells, which in turn were used to define
the regions of interest (ROI). The ROI were transferred
onto the images showing lamin A/C staining. This
approach allows to only consider infected cells in the sta-
tistical analysis, which was performed using the StatView
(SAS Institute Inc.) software.
Caspase 3 activity assay in microwell format
The assay for caspase 3 activity was performed in a 96-well
format using the Caspase-Glo 3/7™ assay (G8090,
Promega) according to the manufacturer's protocol.
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